Kazuhiro Okumura
Overview
Explore the profile of Kazuhiro Okumura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
269
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watanabe H, Kawanishi H, Kobayashi K, Yamane T, Takaoka N, Okada Y, et al.
Hinyokika Kiyo
. 2025 Mar;
71(2):43-48.
PMID: 40033172
Ganglioneuroma, an infrequent benign tumor that originates from the sympathetic nervous system, is usually a solitary occurrence and rarely occurs at multiple sites. Here, we report a case of retroperitoneal...
2.
Kong W, Hara M, Tokunaga Y, Okumura K, Hirano Y, Miao J, et al.
Life Sci Alliance
. 2024 Oct;
8(1).
PMID: 39433344
Establishing the correct kinetochore-microtubule attachment is crucial for faithful chromosome segregation. The kinetochore has various regulatory mechanisms for establishing correct bipolar attachment. However, how the regulations are coupled is not...
3.
Okumura K, Morinaga T, Saito M, Tokunaga Y, Otoyama K, Tanaka S, et al.
Cancer Sci
. 2024 Jun;
115(8):2839-2845.
PMID: 38898727
By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer...
4.
Kobayashi K, Takahashi S, Yasuda M, Miyazaki J, Wada K, Matsumoto M, et al.
J Infect Chemother
. 2024 Apr;
30(7):579-589.
PMID: 38588797
Introduction: Antimicrobial susceptibility patterns of bacterial pathogens isolated from patients with complicated urinary tract infections were analyzed using the national surveillance data, comprising 793 bacterial strains from eight clinically relevant...
5.
Kubota M, Kawakita M, Yoshida S, Kimura H, Sumiyoshi T, Yamasaki T, et al.
Sci Rep
. 2024 Mar;
14(1):5847.
PMID: 38462660
This study aimed to assess the effects of thienopyridine-class antiplatelet agents (including ticlopidine, clopidogrel, and prasugrel) on bleeding complications in patients who underwent robot-assisted radical prostatectomy. This cohort study used...
6.
Okumura K, Morinaga T, Saito M, Tokunaga Y, Otoyama K, Tanaka S, et al.
J Invest Dermatol
. 2024 Feb;
144(8):1890-1893.e5.
PMID: 38325578
No abstract available.
7.
Cash McGinley H, Hancock W, Kern-Allely S, Jenssen M, Chutaro E, Camacho J, et al.
PLOS Glob Public Health
. 2023 Aug;
3(8):e0002052.
PMID: 37585385
The US-Affiliated Pacific Islands (USAPIs) experience many health disparities, including high rates of non-communicable disease and limited health resources, making them particularly vulnerable when SARS-CoV-2 began circulating globally in early...
8.
Takashima Y, Kawanishi H, Kotani S, Watanabe H, Yokozeki H, Funahashi Y, et al.
Hinyokika Kiyo
. 2023 Jul;
69(6):169-173.
PMID: 37460281
The patient was a 79-year-old man with ureteroileal anastomotic stricture after a Bricker ileal conduit. Endourological treatment of stenosis was performed via percutaneous nephrostomy and ileal conduit. The patient experienced...
9.
Patient Characteristics During Early Transmission of SARS-CoV-2, Palau, January 13-February 24, 2022
Eilers B, Adelbai-Fraser M, Collado J, Van Dyke M, Firestone M, Guinn A, et al.
Emerg Infect Dis
. 2023 Jul;
29(9):1939-1941.
PMID: 37437566
Palau had no reported evidence of COVID-19 community spread until January 2022. We chart reviewed hospitalized patients who had a positive SARS-CoV-2 test result during early community transmission. Booster vaccinations...
10.
Isogai E, Okumura K, Saito M, Tokunaga Y, Wakabayashi Y
Biomed Res
. 2022 Jun;
43(3):91-97.
PMID: 35718449
Meis1 (myeloid ecotropic insertion site 1) is known to be related to embryonic development and cancer. In this study, to analyze the function of Meis1 in neural stem cells, we...